Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobus Pfisterer

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinomaIvo Meinhold-Heerlein, Dirk Bauerschlag, Yingyao Zhou, et al.
The Lancet. Oncology|January 22, 2013
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trialDan Stark, Matthew Nankivell, Eric Pujade-Lauraine, et al.
Gynecologic Oncology|November 20, 2018
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancerAntonio González Martín, Amit M Oza, Andrew C Embleton, et al.
Annals of Surgical Oncology|September 30, 2006
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trialPhilipp Harter, Andreas du Bois, Maik Hahmann, et al.
Acta Neuropathologica|January 5, 2018
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degenerationMathilde Small, Isabelle Treilleux, Coline Couillault, et al.
Gynecologic Oncology|July 21, 2019
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 studyLinn Woelber, Christine Eulenburg, Jens Kosse, et al.
Gynecologic Oncology|June 23, 2019
Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter studyRüdiger Klapdor, Linn Wölber, Lars Hanker, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 1, 2019
Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics DimensionsBoris Winterhoff, Stefan Kommoss, Florian Heitz, et al.
The Oncologist|September 19, 2025
Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancerB J Rimel, Eric Pujade-Lauraine, Kathleen Moore, et al.
Archives of Gynecology and Obstetrics|April 12, 2020
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study GroupUlrich Canzler, Hans-Joachim Lück, Petra Neuser, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinomaIvo Meinhold-Heerlein, Dirk Bauerschlag, Yingyao Zhou, et al.
The Lancet. Oncology|January 22, 2013
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trialDan Stark, Matthew Nankivell, Eric Pujade-Lauraine, et al.
Gynecologic Oncology|November 20, 2018
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancerAntonio González Martín, Amit M Oza, Andrew C Embleton, et al.
Annals of Surgical Oncology|September 30, 2006
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trialPhilipp Harter, Andreas du Bois, Maik Hahmann, et al.
Acta Neuropathologica|January 5, 2018
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degenerationMathilde Small, Isabelle Treilleux, Coline Couillault, et al.
Gynecologic Oncology|July 21, 2019
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 studyLinn Woelber, Christine Eulenburg, Jens Kosse, et al.
Gynecologic Oncology|June 23, 2019
Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter studyRüdiger Klapdor, Linn Wölber, Lars Hanker, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 1, 2019
Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics DimensionsBoris Winterhoff, Stefan Kommoss, Florian Heitz, et al.
The Oncologist|September 19, 2025
Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancerB J Rimel, Eric Pujade-Lauraine, Kathleen Moore, et al.
Archives of Gynecology and Obstetrics|April 12, 2020
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study GroupUlrich Canzler, Hans-Joachim Lück, Petra Neuser, et al.
Pageof 10